AsianScientist (Sep. 27, 2019) – Lucence Diagnostics (Lucence), a genomic medicine company focused on personalizing cancer care, announced that it has received the Clinical Laboratory Improvement Amendments (CLIA) certification for its laboratory in Singapore from the US Department of Health and Human Services’ Centers for Medicare & Medicaid Services.
With this US federal certification, Lucence can now receive patient specimens from the US for testing with its LiquidHALLMARK®, its flagship liquid biopsy blood test that simultaneously detects cancer-causing gene mutations and viruses present in 14 types of cancers.
“This is a critical regulatory and commercial milestone for Lucence. We are proud to be the first regional laboratory in Southeast Asia to demonstrate compliance with US federal regulatory standards, over and above our CAP and ISO 15189 Accreditations. We are glad to serve American doctors with our technological innovation in liquid biopsy,” said Dr. Tan Min-Han, CEO and founder of Lucence.
Source: Lucence Diagnostics. Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.